1.4602
Galmed Pharmaceuticals Ltd stock is traded at $1.4602, with a volume of 38,836.
It is up +4.30% in the last 24 hours and down -35.39% over the past month.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
See More
Previous Close:
$1.40
Open:
$1.38
24h Volume:
38,836
Relative Volume:
0.05
Market Cap:
$3.18M
Revenue:
-
Net Income/Loss:
$-6.91M
P/E Ratio:
-0.4479
EPS:
-3.26
Net Cash Flow:
$-6.14M
1W Performance:
+3.56%
1M Performance:
-35.39%
6M Performance:
-69.64%
1Y Performance:
-66.58%
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Name
Galmed Pharmaceuticals Ltd
Sector
Industry
Phone
-
Address
-
Compare GLMD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
GLMD
Galmed Pharmaceuticals Ltd
|
1.4602 | 3.18M | 0 | -6.91M | -6.14M | -3.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-22-20 | Downgrade | B. Riley FBR | Buy → Neutral |
Feb-04-20 | Initiated | Craig Hallum | Buy |
Jan-30-20 | Resumed | Cantor Fitzgerald | Overweight |
Dec-02-19 | Initiated | Canaccord Genuity | Buy |
Dec-12-18 | Initiated | B. Riley FBR | Buy |
Aug-02-18 | Reiterated | Maxim Group | Buy |
Jul-13-18 | Initiated | Stifel | Buy |
Jul-12-18 | Initiated | Cantor Fitzgerald | Overweight |
Jun-12-18 | Reiterated | H.C. Wainwright | Buy |
Mar-15-18 | Upgrade | Maxim Group | Hold → Buy |
Feb-14-18 | Downgrade | Maxim Group | Buy → Hold |
Feb-12-18 | Reiterated | H.C. Wainwright | Buy |
Nov-15-17 | Initiated | ROTH Capital | Buy |
Aug-08-17 | Reiterated | H.C. Wainwright | Buy |
Jul-31-17 | Reiterated | Maxim Group | Buy |
Aug-01-16 | Reiterated | Maxim Group | Buy |
Jul-06-16 | Resumed | ROTH Capital | Buy |
Mar-28-16 | Resumed | H.C. Wainwright | Buy |
Jun-23-15 | Initiated | H.C. Wainwright | Buy |
May-06-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World
Galmed partners with VCU to target drug resistance - The Pharma Letter
Galmed Pharmaceuticals Partners with VCU to Combat Drug Resistance in GI Cancers - TipRanks
Galmed Pharmaceuticals Launches VCU Collaboration To Tackle Drug Resistance In Gi Cancers - marketscreener.com
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers - PR Newswire
Galmed reports key biomarkers for heart and liver health By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals Unveils New Blood Markers for Aramchol - TipRanks
Galmed reports key biomarkers for heart and liver health - Investing.com
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor - Longview News-Journal
Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com - Defense World
Galmed Pharmaceuticals Reports Positive Results from AM-001 Study of Aramchol Meglumine - TipRanks
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor - PR Newswire
Maxim Group Reiterates “Hold” Rating for Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com - Defense World
Galmed Phar stock hits 52-week low at $1.32 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $1.32 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 - Yahoo Finance
Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com - Defense World
Galmed Phar stock hits 52-week low at $1.66 amid challenges - Investing.com India
Galmed Phar stock hits 52-week low at $1.66 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals Secures New Patent for NASH Therapy - TipRanks
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy - PR Newswire
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com - Defense World
Galmed Phar stock hits 52-week low at $1.75 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $1.75 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire
Galmed Phar stock hits 52-week low at $2.21 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $2.21 amid challenges By Investing.com - Investing.com South Africa
StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
Galmed Phar stock hits 52-week low at $2.6 amid market challenges - Investing.com Nigeria
Galmed Phar stock hits 52-week low at $2.6 amid market challenges By Investing.com - Investing.com South Africa
Galmed Phar stock hits 52-week low at $2.71 amid market challenges By Investing.com - Investing.com South Africa
Galmed Phar stock hits 52-week low at $2.71 amid market challenges - Investing.com Nigeria
Galmed Pharmaceuticals: Q3 Earnings Snapshot - New Haven Register
Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):